

Screening

PI or delegate identifies
potential participant



Obtain ICF
(patient, witness or LAR)

Eligibility

- (i) **Hospitalised (planned overnight stay) and aged ≥ 18 years old**
- (ii) **Pneumonia syndrome** (*criteria below are a guide only - diagnosis is based on clinical opinion of the managing doctor*)
 - a) typical symptoms of a new respiratory infection; AND
 - b) objective evidence of acute lung disease (e.g. X-ray/CT, hypoxia, compatible clin. examination); AND
 - c) alternative causes are unlikely or excluded (e.g. heart failure)
- (iii) **No medical history that might put patient at significant risk if participating in the trial**
- (iv) **Clinician does not believe a specific trial treatment is indicated or contra-indicated**
- (v) **One of the following diagnoses:**

Confirmed influenza A or B

Patients can enter all three comparisons if eligible

OR

CAP with planned antibiotic treatment

(**without** suspected SARS-CoV-2, influenza, active pulmonary tuberculosis or *Pneumocystis jirovecii pneumonia*)

Open to all patients
weighing ≥ 40 kg
except if pregnant
or breastfeeding

Open
to all
patients

Open for patients:
1) with hypoxia (on O2 or Sats $<92\%$)
2) without suspected SARS-CoV-2

**Baloxavir OR
usual care *without*
baloxavir**

**Oseltamivir OR
usual care *without*
neuraminidase
inhibitor**

**Dexamethasone (6 mg
daily)[†] OR usual care
without systemic
corticosteroids**

**Dexamethasone (6 mg
daily)[†] OR usual care
without systemic
corticosteroids**

[†]prednisolone/hydrocortisone in case of pregnancy/breastfeeding

Refer to Intervention Sheets for detailed treatment and dosing guide, available at www.recoverytrial.net/eu

Not all treatment comparisons may be open at your site – check with the study team

